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Introduction
Breast carcinoma is the most prevalent cancer and the leading cause of cancer deaths in woman in the world today (1) . Mortality from breast cancer is invariably due to metastasis, the dissemination of cancer cells from the primary tumor to distant organs, such as the lungs, bones, brain and liver, via lymphatic and/or hematogenous routes. Metastasis is a complex, step-wise process whereby tumor cells migrate and invade the surrounding stroma, intravasate into the circulation, extravasate into distant organs, and colonize the organ microenvironment (2) . At each step, tumor cells must escape apoptosis in order to survive detachment from the extracellular matrix of the primary tumor ("anoikis"), in the circulation and in the organ microenvironment (3) . Current adjuvant therapies for breast cancer, including radiation and chemotherapy, are often ineffective against metastases (4) . Thus, new therapeutic agents for advanced breast cancer are greatly needed to improve the prognosis for patients with this largely incurable stage of the disease.
Therapeutic targeting of the apoptotic machinery in cancer cells has emerged as a promising approach with the potential to overcome many of the shortcomings of non-selective cytotoxic agents. Indeed, (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L) is a proapoptotic cytokine in the TNF-α family that has emerged as a promising cancer therapeutic agent because of its relative tumor-specificity and limited toxicity (5, 6) . TRAIL initiates apoptosis by binding to its proapoptotic receptors, TRAIL receptor-1 (TRAIL-R1/DR4) and TRAIL receptor-2 (TRAIL-R2/DR5), which recruit the adaptor protein FADD to their cytoplasmic death domains. FADD then recruits procaspases-8 and 10 to ligand-activated TRAIL-R1 and TRAIL-R2, resulting in dimerization-mediated activation of caspases-8 and 10, the initiator caspases in the extrinsic or death receptor apoptotic pathway. Other TRAIL with neutralizing anti-TRAIL antibodies in several tumor models (7, 8) . Genetic deletion of the single proapoptotic TRAIL receptor in mice promotes c-myc-mediated lymphomas and visceral metastases to the lungs and liver (9) . Furthermore, TRAIL-R-deficient mice are no more susceptible to carcinogen-induced skin papillomas and squamous cell carcinomas than wild-type mice, but TRAIL-R-deficient mice develop more lymph node metastases (10) . Collectively, these findings suggest that TRAIL may function primarily as a metastasis suppressor. Consistent with this idea, matrix-detachment induced apoptosis or anoikis, which functions as a barrier against metastasis, is mediated by TRAIL-induced activation of TRAIL-R2 in colorectal carcinoma cells (11) .
Extensive preclinical studies have demonstrated that TRAIL and agonistic monoclonal antibodies (mAbs) targeting TRAIL-R1 or TRAIL-R2 preferentially activate apoptosis in cancer cells versus non-transformed cells, reduce tumor burden in vivo, and have little systemic toxicity (12) (13) (14) (15) (16) (17) . Recently, several proapoptotic death receptor agonists, including recombinant human TRAIL (dulanermin) and fully humanized agonistic monoclonal antibodies (mAbs) targeting TRAIL-R1/DR4 (mapatumumab) or TRAIL-R2/DR5 (lexatumumab, PRO95780, conatumumab and CS-1008) have been evaluated as single agents or in combination with chemotherapy in early clinical trials in patients with advanced malignancies (18) (19) (20) (21) (22) (23) (24) (25) . Although all of these agents appear to be well tolerated in patients, TRAIL receptor mAbs have several potential therapeutic (18) . Despite these potential advantages, it is unclear whether TRAIL-R1 or TRAIL-R2 is a better therapeutic target for metastatic breast cancer. Importantly, both TRAIL-R1 and TRAIL-R2 are expressed in the vast majority of human breast cancer cell lines and human breast tumors (26) (27) (28) . Recent studies suggest that TRAILinduced apoptosis in different tumor types may be mediated by distinct TRAIL receptors (29) (30) (31) . One study reported that TRAIL-induced apoptosis in a subset of human breast cancer cell lines, which are "triple negative" for the estrogen receptor, the progesterone receptor and HER2 gene amplification, is mediated by TRAIL-R2 in vitro (32) . However, it remains to be determined whether TRAIL-R2 is the principal proapoptotic death receptor in breast tumors in vivo and whether targeting TRAIL-R2 confers greater antimetastatic activity in vivo than targeting TRAIL-R1.
To this end, we examined the sensitivity of several human metastatic, triple-negative cancer cell lines to apoptosis induction by fully human agonistic mAbs targeting TRAIL-R1 (mapatumumab) or TRAIL-R2 (lexatumumab). Here we report that lexatumumab is more effective than mapatumumab in activating caspase-8, inducing apoptosis and inhibiting longterm survival of these metastatic cancer cell lines in vitro. Importantly, transformed human breast epithelial cells are more sensitive to lexatumumab than non-transformed cells, confirming the preferential proapoptotic activity of this agent against cancer cells. To evaluate the antimetastatic activity of these agents in vivo, we developed an orthotopic model that utilizes mCherry-labeled human MDA-MB-231 triple negative breast cancer to quantitate lymph node and lung metastases in vivo. Both lexatumumab and mapatumumab inhibited mammary tumor growth and lung metastases in vivo, although lexatumumab was more effective than mapatumumab at reducing lymph node and lung metastases. Intriguingly, doxorubicin was more effective at inhibiting mammary tumor growth than either TRAIL receptor agonist, but was less effective than lexatumumab at reducing lung metastases. Taken together, our findings strongly suggest that TRAIL-R2 may be a promising therapeutic target in metastatic breast cancer. (Invitrogen), 20 ng/ml EGF, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 μg/ml insulin (Sigma-Aldrich), and 100 IU/ml penicillin-streptomycin. Human BxPC3 pancreatic adenocarcinoma cells (kindly provided by Dr. Hidayatullah Munshi, Northwestern University) were cultured in DMEM supplemented with 10% FBS and 100 IU/ml penicillin/streptomycin.
Material and Methods

Cell
Mapatumumab and lexatumumab were kindly supplied by Dr. Robin Humphreys (Human Genome Sciences) (15, 16) . Doxorubicin (Sigma-Aldrich) was dissolved in DMSO.
Immunoblotting. Proteins were immunoblotted from whole cell lysates as described (39) . 
Results
Human metastatic, triple-negative cancer cells are more sensitive to cell death induction by lexatumumab than mapatumumab. We chose three human triple-negative cancer cell lines, MDA-MB-231, GILM2 and MDA-MB-435-Lung2 (abbreviated 435-Lung2), which metastasize to the lungs for these studies (34) (35) (36) . Before evaluating the sensitivity of these cell lines to human agonistic mAbs targeting TRAIL-R1 (mapatumumab) or TRAIL-R2 (lexatumumab), we examined the expression of these proapoptotic TRAIL receptors in the cell lines by immunoblotting. Both TRAIL-R1 and TRAIL-R2 were highly expressed in each of these metastatic cancer cell lines (Fig. 1A) . Moreover, flow cytometry revealed that both TRAIL receptors were expressed on the cell surface of each cancer cell line (Fig. 1B) . Despite expression of both proapoptotic death receptors, all three cancer cell lines were more sensitive to lexatumumab (Lexa) than mapatumumab (Mapa) as determined by an MTS cell viability assay in dose-response and time course studies (Fig. 1C) . The IC 50 values for lexatumumab were 0.13 µg/mL for MDA-MB-231 cells, 0.23 µg/mL for 435-Lung2 cells, and 0.19 µg/mL for GILM2 cells. The cytotoxic agent doxorubicin (Dox) was used as a positive control in these studies. In contrast, human BxPC3 pancreatic adenocarcinoma cells were more sensitive to mapatumumab than lexatumumab at the highest concentration tested (Fig. 1D) , consistent with a prior report (31) . To determine whether mapatumumab or lexatumumab suppressed long-term cell survival, cancer cell lines were treated with vehicle, mapatumumab (0.5 µg/mL), lexatumumab (0.5 µg/mL) or Dox (0.2-0.5 μM) for 48 h, washed, and then grown for 5-7 days in the absence of (Fig. 2C, left panel) . Transformed MCF-10A-H-RasV12 cells were more sensitive to lexatumumab than non-transformed MCF-10A-Vector cells, confirming the preferential proapoptotic activity of this agent against cancer cells. Interestingly, neither of these cell lines was sensitive to mapatumumab, although they expressed TRAIL-R1 (data not shown). The enhanced sensitivity of transformed MCF-10A-HRasV12 cells to lexatumumab was also observed in dose-response experiments using an MTS assay (Fig. 2C, right panel) . Taken (Table 1) . Doxorubicin (5 mg/kg weekly x 3), a commonly used cytotoxic agent in breast cancer, was used as a control. Both lexatumumab and mapatumumab inhibited mammary tumor growth and there was a trend toward smaller tumors in the lexatumumab group, but this difference was not statistically significant (Fig. 4A) . Doxorubicin was more effective at inhibiting mammary tumor growth than either TRAIL receptor agonist (Fig. 4A) . However, doxorubicin treatment resulted in weight loss, and two doxorubicin treated mice died during the study (data not shown). Both TRAIL receptor agonists and doxorubicin induced apoptosis in mammary tumors as determined by cleaved caspase-3 immunostaining (Fig. 4B) . Consistent with our in vitro findings, lexatumumab induced apoptosis more potently than mapatumumab in mammary tumors in vivo.
To evaluate the impact of each therapeutic agent on metastases in vivo, mice were euthanized 45 days after intraductal tumor inoculation, and metastases (lymph nodes and lung) were scored at autopsy. Both lexatumumab and doxorubicin reduced the number of lymph node metastases, while mapatumumab did not ( Table 2 ). All three agents reduced lung metastases compared to vehicle control ( Table 2 and Fig. 4C) . Importantly, only one of ten mice in the lexatumumab group developed lung metastases, whereas 5 of 11 mice in the mapatumumab and doxorubicin groups developed lung metastases. To more precisely quantitate the effects of each treatment on metastatic tumor burden in the lungs, the number of metastases per lung (Fig. 4C, left panel) and the surface area of lung occupied by metastases (Fig. 4C, right panel) was calculated by fluorescence imaging. Although all 3 agents reduced the number of lung metastases and surface area occupied by lung metastases, lexatumumab was more effective than mapatumumab or doxorubicin at reducing lung metastatic burden. Collectively, our findings point to TRAIL-R2 as a promising therapeutic target in metastatic triple-negative breast cancer.
Discussion
Although recent studies point to a critical role of the endogenous TRAIL proapoptotic pathway in metastasis suppression, the specific contribution of TRAIL-R1 versus TRAIL-R2 in mediating these actions in vivo has not been delineated (7) (8) (9) (10) . Hence, it remains to be determined whether TRAIL-R1 or TRAIL-R2 is a better therapeutic target in metastatic solid tumors such as breast cancer. To directly address this question, we examined the sensitivity of human metastatic, triple-negative cancer cells to fully human agonistic mAbs targeting TRAIL- 
R1 (mapatumumab) or TRAIL-R2 (lexatumumab) in vitro and in vivo.
We have demonstrated that lexatumumab is more effective than mapatumumab in activating caspase-8, inducing apoptosis and inhibiting long-term survival of several metastatic, triple-negative cancer cell lines in vitro. The mechanism(s) underlying the enhanced sensitivity of these metastatic cancer cell lines to lexatumumab is unclear: both TRAIL-R1 and TRAIL-R2 are expressed on the cell surface of these cancer cell lines. We also observed that transformed human mammary epithelial cells are more sensitive to lexatumumab than non-transformed cells, consistent with the welldocumented tumor-selectivity of proapoptotic receptor agonists (5, 6) . Additionally, we have demonstrated that lexatumumab is more effective than mapatumumab at suppressing lung and lymph node metastases in an orthotopic model of triple-negative breast cancer. Interestingly, we observed that lexatumumab is also more effective than doxorubicin at suppressing metastases in vivo at doses of doxorubicin that were associated with systemic toxicity and some mortality, even though doxorubicin treatment reduced primary tumor burden more robustly than lexatumumab. Hence, our results point to a promising therapeutic role for specifically targeting TRAIL-R2 in metastatic breast cancer that is consistent with the documented physiologic function of the TRAIL pathway in metastasis suppression.
Although TRAIL and an agonistic TRAIL-R2 mAb (Apomab) were previously reported to inhibit bone metastases induced by intratibial injection of breast cancer cells (42, 43) Our results are consistent with a recent report demonstrating that TRAIL-induced apoptosis is mediated specifically by TRAIL-R2 in a subset of triple-negative breast cancer cell lines in vitro (32) . Triple-negative breast tumors, which express basal epithelial genes, such as cytokeratin 5 and vimentin, are associated with poor survival due to frequent metastases to the lung and brain within the first five years of diagnosis (44) . Although many breast cancer cell lines are resistant to TRAIL alone, triple-negative breast carcinoma cell lines with a mesenchymal phenotype, defined by vimentin expression, are selectively sensitive to TRAILinduced apoptosis in vitro, while triple-negative breast cancer cells which express epithelial markers such as E-cadherin are largely resistant to TRAIL (26, 32) . These latter findings suggest that the epithelial mesenchymal transition (EMT), a process implicated in tumor progression to an invasive, metastatic phenotype (45), may be accompanied by the acquisition of TRAILsensitivity. Intriguingly, the expression of TRAIL-R2, but not TRAIL-R1, is higher in malignant breast tumors than normal breast tissue and is associated with estrogen receptor-negative status, lymph node metastases and poor survival, suggesting that TRAIL-R2 levels may increase with disease progression (27, 28) . Taken together, these results suggest that TRAIL-R2 may be a promising drug target in poor prognosis triple-negative breast cancer, which currently lack targeted therapies.
Research. solid tumors, such as pancreatic adenocarcinomas, appears to be mediated predominantly by TRAIL-R1 (30, 31) , our results strongly underscore the rationale for specifically targeting TRAIL-R2 in poor prognosis triple-negative breast cancer, which frequently metastasizes to the lungs and brain despite adjuvant chemotherapy and radiation (44) . Of note, the differential sensitivity of various tumor types to TRAIL-R1 or TRAIL-R2 agonists is poorly understood and will require further study to delineate the underlying molecular mechanisms. Nevertheless, given the lack of targeted agents for triple-negative breast cancer, the clinical translation of TRAIL-R2 agonists, alone and/or in combination with chemotherapy, has the potential to improve the clinical outcome for these patients who are at high risk for disease progression in the first few years after diagnosis. as determined by ex vivo fluorescence imaging of isolated whole lungs (mean ± SEM, n=10-11 mice per group). *P < 0.05, **P < 0.01 or ***P < 0.001 for the indicated comparisons. Research. 
